Vildagliptin: Clinical trials programme in monotherapy and combination therapy for type 2 diabetes

International Journal of Clinical Practice

Volumn 62, Issue SUPPL. 159, 2008, Pages 15-23

  Rosenstock, J ^a,b   Fitchet, M ^c  

^a DALLAS DIABETES AND ENDOCRINE CENTER AT MEDICAL CITY   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; GLIMEPIRIDE; GLITAZONE DERIVATIVE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; METFORMIN; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SULFONYLUREA; VILDAGLIPTIN;

ABDOMINAL PAIN; ADD ON THERAPY; BODY MASS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DATA ANALYSIS; DIARRHEA; DIZZINESS; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; GASTROINTESTINAL SYMPTOM; GLUCOSE TOLERANCE; GLYCEMIC CONTROL; HEADACHE; HEMOGLOBIN DETERMINATION; HUMAN; HYPOGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; LIPID ANALYSIS; LOW DRUG DOSE; METHODOLOGY; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL EDEMA; PRIORITY JOURNAL; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; WEIGHT GAIN;

EID: 38949131483     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2007.01692.x     Document Type: Review

References (17)

1. Nathan DM, Buse JB, Davidson MB et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006 29 : 1963 72.
2. Barnett A. DPP-4 inhibitors and their potential role in the management of type 2 diabetes. Int J Clin Pract 2006 60 : 1454 70.
3. Rosenstock J, Zinman B. Dipeptidyl peptidase-4 inhibitors and the management of type 2 diabetes mellitus. Curr Opin Endocrinol Diabetes Obes 2007 14 : 98 107.
4. Balas B, Baig MR, Watson C et al. The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients. J Clin Endocrinol Metab 2007 92 : 1249 55.
5. Pi-Sunyer FX, Schweizer A, Mills D, Dejager S. Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes. Diabetes Res Clin Pract 2007 76 : 132 8.
6. Rosenstock J, Baron MA, Dejager S, Mills D, Schweizer A. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Care 2007 30 : 217 23.
7. Schweizer A, Couturier A, Foley JE, Dejager S. Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug-naive patients with type 2 diabetes. Diabet Med 2007 24 : 955 61.
8. Rosenstock J, Pi-Sunyer FX, Pratley RE, Couturier A, Schweizer A, Dejager S. Robust efficacy of vildagliptin in drug-naïve patients: pooled analysis of 5 monotherapy studies. Diabetes 2007 56 : A135 (Abstract 506-P).
9. Nathwani A. The use of vildagliptin for treatment of patients with type 2 diabetes mellitus. Presented at the 66th scientific sessions of the American Diabetes Association; June 9-13, 2006 Washington, DC.
10. Pratley RE, Rosenstock J, Pi-Sunyer FX, Couturier A, Schweizer A, Dejager S. Benefit/risk assessment of vildagliptin in the elderly: pooled analysis of 5 monotherapy studies. Diabetes 2007 56 : A135 (Abstract 507-P).
11. Rosenstock J, Foley JE, Rendell M et al. Effects of the DPP-4 inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Diabetes Care 2008 31 : 30 5.
12. Bosi E, Camisasca RP, Collober C, Rochotte E, Garber AJ. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 2007 30 : 890 5.
13. Bolli G, Dotta F, Rochotte E, Cohen SE. Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study. Diabetes Obes Metab 2008 10 : 82 90.
14. Garber AJ, Schweizer A, Baron MA, Rochotte E, Dejager S. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. Diabetes Obes Metab 2007 9 : 166 74.
15. Garber AJ, Dejager S, Foley JE, Jauffret S, Baron MA. Efficacy and tolerability of vildagliptin added to sulfonylurea (SU) in patients with type 2 diabetes (T2DM). Presented at the 67th Scientific Sessions of the American Diabetes Association, June 22-26 2007 Chicago, IL.
16. Rosenstock J, Baron MA, Camisasca R-P, Cressier F, Couturier A, Dejager S. Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes. Diabetes Obes Metab 2007 9 : 175 85.
17. Fonseca V, Schweizer A, Albrecht D, Baron MA, Chang I, Dejager S. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia 2007 50 : 1148 55.